Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 1/2 1

Status

Completed 3Recruiting 2

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 5

Conditions

Lymphoma, Non-Hodgkin 130Lymphoma, Large B-Cell, Diffuse 101Lymphoma, Follicular 90Leukemia, Lymphocytic, Chronic, B-Cell 82Lymphoma 63Lymphoma, B-Cell 43Recurrence 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 23Neoplasms 22Leukemia 10Hematologic Diseases 10Lymphatic Diseases 8Multiple Myeloma 7Immunoproliferative Disorders 6Hematologic Neoplasms 6Waldenstrom Macroglobulinemia 5Lymphoproliferative Disorders 5Leukemia, B-Cell 5Arthritis, Rheumatoid 5Hodgkin Disease 4Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Immune System Diseases 3Dendritic Cell Sarcoma, Interdigitating 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2

Interventions

ofatumumab 10ibrutinib 6Rituximab 5acalabrutinib 4Cyclophosphamide 3spebrutinib 2pirtobrutinib 2obinutuzumab 2navitoclax 2fludarabine phosphate 2Tablets 2Lenalidomide 2KW-2478 2Chlorambucil 2Antigens, CD19 2ARQ531 2venetoclax 1tirabrutinib 1pomalidomide 1pivalyloxymethyl butyrate 1immunotoxin HA22 1idelalisib 1idecabtagene vicleucel 1fludarabine 1dinaciclib 1bempegaldesleukin 1Vincristine 1Rabeprazole 1Prednisone 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, B-Cell × Rituximab × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06564038 2026-05-14

Soundtrack-E

AstraZeneca

Phase 1/2 Recruiting
408 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

AbbVie

Phase 1 Completed
29 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT03582098 2019-04-12

RETRO-idel

Gilead Sciences

Completed
112 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT01744626 2016-04-19

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Celgene Corporation

Phase 1 Completed
40 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡